Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04724239 |
TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | 阶段
第二阶段
|
Date Added 2021-01-26 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
chidamide, IBI305, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT03093116 |
TitleRepotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2017-03-28 |
地点
California, United States
Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 澳大利亚 比利时 加拿大 中国 丹麦 法国 德国 香港 Hungary 意大利 日本 大韩民国 荷兰 波兰 新加坡 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
口服雷博替尼（TPX-0005） |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05677113 |
TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver | 阶段
第二阶段
|
Date Added 2023-01-10 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Placebo, QBECO |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05107674 |
TitleA Study of NX-1607 in Adults With Advanced Malignancies | 阶段
第 1 阶段
|
Date Added 2021-11-04 |
地点
California, United States
Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
NX-1607 |
标签
MSS/ MMRp
|
| NCT ID NCT06218914 |
TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | 阶段
第 1 阶段
|
Date Added 2024-01-23 |
地点
California, United States
Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06792695 |
TitleA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | 阶段
第二阶段
|
Date Added 2025-03-25 |
地点
Arizona, United States
California, United States District of Columbia, United States Illinois, United States Maryland, United States Massachusetts, United States Minnesota, United States New York, United States Ohio, United States Texas, United States 澳大利亚 加拿大 中国 法国 德国 意大利 大韩民国 西班牙 台湾 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT04008030 |
TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW ) | 阶段
第三阶段
|
Date Added 2019-07-05 |
地点
California, United States
Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States 阿根廷 澳大利亚 Austria 比利时 巴西 加拿大 智利 中国 Czechia 丹麦 法国 德国 希腊 Ireland 意大利 日本 荷兰 挪威 波多黎各 Romania 西班牙 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT05328908 |
Title一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究 | 阶段
第三阶段
|
Date Added 2022-04-14 |
地点
Arkansas, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States 阿根廷 澳大利亚 Austria 比利时 加拿大 智利 中国 Czechia 法国 德国 意大利 日本 大韩民国 荷兰 波兰 波多黎各 新加坡 西班牙 瑞典 瑞士 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga |
标签
MSS/ MMRp
|
| NCT ID NCT04426669 |
Title利用 CRISPR 基因工程抑制编码细胞内免疫检查点 CISH 基因的肿瘤浸润淋巴细胞治疗转移性胃肠癌的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2020-06-11 |
地点
Minnesota, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT01351103 |
TitleA Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | 阶段
第 1 阶段
|
Date Added 2011-05-10 |
地点
California, United States
Maryland, United States Massachusetts, United States Michigan, United States Texas, United States 加拿大 法国 德国 意大利 荷兰 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
LGK974, PDR001 |
标签
MSS/ MMRp
|
